0
Abstract: Poster Presentations |

USE OF FONDAPARINUX AS TREATMENT FOR THROMBOEMBOLIC EVENTS IN ONCOLOGY PATIENTS: A DESCRIPTIVE EPIDEMIOLOGIC STUDY FREE TO VIEW

Shannon L. Michels, MSPH; Jill Abell, PhD; Ruslan Horblyuk, MA*; Beth Nordstrom, PhD
Author and Funding Information

GlaxoSmithKline, Philadelphia, PA


Chest


Chest. 2008;134(4_MeetingAbstracts):p59003. doi:10.1378/chest.134.4_MeetingAbstracts.p59003
Text Size: A A A
Published online

Abstract

PURPOSE: Malignancy is associated with a hypercoagulable state and an increased risk of venous thromboembolism (VTE). Limited data are available on the real-world treatment patterns associated with the antithrombotic agent fondaparinux in this population. This study looked at the use of fondaparinux treatment in cancer patients.

METHODS: Data were extracted from the Varian Medical Oncology database of electronic medical records from 17 outpatient oncology clinics in the US. Adults with any cancer treated with fondaparinux at a dose 5.0mg, 7.5mg, 10.0mg or higher between January 2001 and September 2007 were identified. Demographics, clinical characteristics, chemotherapy regimens, and treatment patterns were derived and summarized.

RESULTS: A total of 101 patients were treated with fondaparinux with the majority receiving a dose of 7.5 mg/day [81.2%]. The mean age of this population was 60.5 years and 58% were women. Approximately 70% had a solid tumor (15% breast, 18% lung, 6% colorectal and 31% other), 8% had hematological malignancies and 7% had multiple diagnoses. Nearly half of the patients had stage IV and/or evidence of metastases. Approximately 79% of patients received chemotherapy. Fondaparinux was administered more frequently after chemotherapy [68%] than concurrently with chemotherapy [11%]. Approximately 59% of patients received concomitant vitamin K inhibitor. Assuming all prescriptions and refills were filled and taken, the median duration of continuous use ranged from 1–402 days (median of 5 days). The median duration of fondaparinux use, allowing for treatment gaps, was 8 days (range 1–480 days). A total of 30 patients used fondaparinux long-term (>30 days), 14 patients for 1–3 months, 8 patients for 3–6 months, and 8 patients for more than 6 months.

CONCLUSION: In this sample of US oncology clinics, 101 patients with varying types of cancers, were treated with fondaparinux for a median of eight days. One-third of these patients were treated for more than 1 month and 8% were for more than 6 months.

CLINICAL IMPLICATIONS: In real-world clinical practice, fondaparinux is used for VTE treatment of various duration in a heterogeneous cancer patient population.

DISCLOSURE: Ruslan Horblyuk, Other United BioSource Corporation received funding for this project from GlaxoSmithKline; No Product/Research Disclosure Information

Tuesday, October 28, 2008

1:00 PM - 2:15 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543